퀀타매트릭스
Financials
Valuation Metrics
퀀타매트릭스's Market Cap is ₩405B. At end of 2025 it was ₩964B. Ranked #1842 of 2,405 in KR market (top 77%), #1140 of 1,627 on KOSDAQ (top 70%), #195 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 84%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 40.47B KRW | KR#1,842/2,405 Sec#195/231 |
| Revenue | 3.15B KRW | KR#2,353/2,405 Sec#205/231 |
| Net Income | -17.85B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 43.22B KRW | KR#2,252/2,405 Sec#207/231 |
| Net Assets | 32.10B KRW | KR#2,144/2,405 Sec#191/231 |
| Employees | 91 | KR#1,708/2,405 Sec#135/231 |
| Value | ||
| P/B | 1.26x | KR#1,710/2,405 Sec#116/231 |
| P/S | 12.87x | KR#2,298/2,405 Sec#175/231 |
| FCF Yield | -38.57% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -55.60% | KR#2,278/2,405 Sec#199/231 |
| ROA | -41.29% | KR#2,335/2,405 Sec#212/231 |
| Op. Margin | -526.81% | KR#2,350/2,405 Sec#206/231 |
| Revenue Growth | 4.26% | KR#1,235/2,405 Sec#123/231 |
| Financial Health | ||
| Debt Ratio | 34.65% | KR#679/2,405 Sec#82/231 |
| Total Debt | 6.99B KRW | KR#1,717/2,405 Sec#161/231 |
| FCF | -15.61B KRW | KR#1,823/2,405 Sec#171/231 |
| Cash | 4.56B KRW | KR#2,025/2,405 Sec#189/231 |
| Current Ratio | 3.91x | KR#395/2,405 Sec#62/231 |
| Performance | ||
| 1Y Return | -51.86% | KR#2,026/2,405 Sec#176/231 |
| 1M Return | -12.80% | KR#1,400/2,405 Sec#140/231 |
| From 52W High | -64.49% | KR#1,855/2,405 Sec#153/231 |
| 1Y MDD | -61.62% | KR#1,537/2,405 Sec#125/231 |
| Trading | ||
| Volume | 29,213 shares | KR#1,289/2,405 Sec#126/231 |
| Trading Value | 59.5M KRW | KR#1,644/2,405 Sec#171/231 |
| Foreign Own. | 18.26% | KR#256/2,405 Sec#14/231 |
| Per Share | ||
| EPS | -886 KRW | KR—/2,405 Sec—/231 |
| BPS | 1,594 KRW | KR#2,171/2,405 Sec#185/231 |
Company Info
Established in 2010 and listed on KOSDAQ in 2020, this company specializes in in vitro diagnostic medical devices. It develops microbial diagnostic technology-based testing systems (dRAST, QDST), molecular immunology platforms (QMAP), and automation equipment (QMIA), which are sold to advanced general hospitals both domestically and internationally. The company is also developing the uCIA system and pursuing the commercialization of the QPLEX Alz plus Assay kit for early diagnosis of Alzheimer's disease. Quantamatrix, established in 2010, is headquartered in Seoul Metropolitan City, Geumcheon-gu.